Lutz Hegemann

Global Head of Development Unit Established Medicines & Anti-Infectives

Dr. Hegemann oversees Novartis’ efforts in drug development to reduce the global burden of infectious and tropical diseases, including malaria.  He also holds responsibility for the Established Medicines portfolio, which com­prises more than 100 medicinal pro­ducts, where he and his team focus on the continuous development and optimization with special emphasis on medical needs in underserved populations.

Dr. Hegemann studied at the University of Bonn (Germany) and the University of Utrecht (The Netherlands).  He holds a medical doctorate and a PhD in Molecular Pharmacology.  He trained as a derma­tologist and has held leadership roles in drug development, spanning preclinical and clinical research, drug safety and regulatory affairs, with several pharma­­ceu­ti­cal companies for the last two decades.